- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03315364
Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy (OPTIMAL)
December 26, 2023 updated by: Daehwa Pharmaceutical Co., Ltd.
A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Liporaxel® (Oral Paclitaxel) Compared to Taxol® (IV Paclitaxel) as First-line Therapy in Patients With Recurrent or Metastatic HER2 Negative Breast Cancer
To compare and evaluate the efficacy and safety of Liporaxel® solution (oral paclitaxel) and Taxol® (IV paclitaxel) on recurrent or metastatic breast cancer.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
549
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sung-bae Kim, M.D., Ph.D
- Phone Number: 82-2-3010-3217
- Email: sbkim3@amc.seoul.kr
Study Locations
-
-
-
Burgas, Bulgaria, 8000
- Oncology Complex Center - Burgas'' Ltd., Medical Oncology Department
-
Panagyurishte, Bulgaria, 4500
- Multi-profile Hospital for Active Treatment Uni Hospital Ltd. Medical Oncology Department
-
Sofia, Bulgaria, 1330
- Medical Center Nadezhda Clinical" Ltd.,
-
-
-
-
-
Zhengzhou, China
- Henan Cancer Hospital
-
-
Anhui
-
Hefei, Anhui, China
- Anhui Cancer Hospital
-
-
Beijing
-
Beijing, Beijing, China
- Cancer Hospital Chinese Academy of Medical Sciences
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Sun Yat-sen University Cancer Center
-
-
Hainan
-
Haikou, Hainan, China
- The First Affiliated Hospital Of Hainan Medical College
-
-
Heilongjiang
-
Harbin, Heilongjiang, China
- Harbin Medical University Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, China
- Tianjin Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Jiangsu Province Hospital
-
Nanjing, Jiangsu, China
- Jiangsu Cancer Hospital
-
-
Jilin
-
Changchun, Jilin, China
- First Affiliated Hospital of Jilin University
-
-
Liaoning
-
Shenyang, Liaoning, China
- Liaoning Cancer Hospital
-
-
Shandong
-
Jinan, Shandong, China
- Shangdong Cancer Hospital
-
Linyi, Shandong, China
- Linyi Cancer Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China
- Fudan University Shanghai Cancer Center
-
-
Shanxi
-
Xi'an, Shanxi, China
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Sichuan
-
Chengdu, Sichuan, China
- West China School Of Medicine Sichuan University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Zhejiang Cancer Hospital
-
Hangzhou, Zhejiang, China
- Zhejiang University School Of Medicine Sir Run Run Shaw Hospital
-
-
-
-
-
Szekszárd, Hungary, 7100
- Tolna County Balassa János Hospital
-
Tatabánya, Hungary, 2800
- Szent Borbála Hospital
-
-
-
-
-
Busan, Korea, Republic of
- Kosin University Gospel Hospital
-
Busan, Korea, Republic of, 612-896
- Inje University Haeundae Paik Hospital
-
Busan, Korea, Republic of
- Pusan National University Yangsan Hospital
-
Daegu, Korea, Republic of
- Keimyung University Dongsan Medical Center
-
Daejeon, Korea, Republic of, 35365
- Konyang University Hospital
-
Gangneung, Korea, Republic of
- Gang Neung Asan Hospital
-
Incheon, Korea, Republic of
- Gachon University Gil Medical Center
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
Seoul, Korea, Republic of
- Gangnam Severance Hospital
-
Seoul, Korea, Republic of, 05505
- Asan Medical Center
-
Seoul, Korea, Republic of, 02841
- Korea University Anam Hospital
-
Seoul, Korea, Republic of, 08308
- Korea University Guro Hospital
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center
-
Seoul, Korea, Republic of, 03722
- Yonsei University Severance Hospital
-
Seoul, Korea, Republic of
- Catholic University of Korea Seoul St. Mary's Hospital
-
Uijeongbu, Korea, Republic of
- Uijeongbu St. Mary's Hospital
-
-
Chungcheongbuk-do
-
Cheongju-si, Chungcheongbuk-do, Korea, Republic of, 28644
- Chungbuk National University Hospital
-
-
Gangwon-do
-
Wŏnju, Gangwon-do, Korea, Republic of, 220-701
- Wonju Severance Christian Hospital
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Korea, Republic of, 10408
- National Cancer Center
-
Seongnam, Gyeonggi-do, Korea, Republic of, 13496
- Cha University Cha Bundang Medical Center
-
Suwon, Gyeonggi-do, Korea, Republic of, 16499
- Ajou University Hospital
-
-
-
-
-
Belgrade, Serbia, 11000
- Institute for Oncology and Radiology of Serbia
-
Belgrade, Serbia, 11080
- Clinical Hospital Center Bežanijska Kosa, Department of Oncology
-
Kladovo, Serbia, 19320
- Health Center Kladovo, Oncology Department
-
Kragujevac, Serbia, 34000
- Clinical Center Kragujevac Center of Oncology and Radiotherapy
-
Kruševac, Serbia, 37000
- General Hospital Krusevac, Outpatient Clinic for chemotherapy
-
Niš, Serbia, 18000
- Clinical Center Niš, Clinic for Oncology
-
Sremska Kamenica, Serbia, 21204
- Oncology Institute of Vojvodina
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key inclusion/exclusion criteria
- Histologically or cytologically confirmed to have recurrent, or metastatic breast cancer.
- Measurable disease (revised RECIST, version 1.1).
- Hormone receptor (ER/PR) positive or negative, HER2 negative.
- Subjects were eligible for the study regardless of their previous lines of endocrine therapy.
- No prior chemotherapy is allowed in metastatic disease.
- Subjects who administrated the last dose of taxane class drug ≥12months ago as from the first administration day.
- ECOG performance status ≤1.
- Neuropathy grade <2.
- Subjects with central nervous system metastasis should be excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Liporaxel® (oral paclitaxel)
|
Oral administration on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
Other Names:
|
Active Comparator: Taxol® (IV paclitaxel)
|
Premedication, intravenous infusion on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
[Phase II] Objective Response Rate (ORR)
Time Frame: Participants will be followed every 6 weeks until progression, an expected average of 9 months.
|
Objective Response Rate (ORR) is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1)
criteria.
|
Participants will be followed every 6 weeks until progression, an expected average of 9 months.
|
[Phase III] Progression Free Survival (PFS)
Time Frame: From date of randomization, assessed up to 18 months.
|
Progression Free Survival (PFS) is defined as the time from date of randomization until the date of first documented progression or death
|
From date of randomization, assessed up to 18 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
[Phase II] Progression Free Survival (PFS)
Time Frame: From date of randomization, assessed up to 18 months.
|
Progression Free Survival (PFS) is defined as the time from date of randomization until the date of first documented progression or death
|
From date of randomization, assessed up to 18 months.
|
[Phase III] Objective Response Rate (ORR)
Time Frame: Participants will be followed every 6 weeks until progression, an expected average of 9 months.
|
Objective Response Rate (ORR) is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1)
criteria.
|
Participants will be followed every 6 weeks until progression, an expected average of 9 months.
|
[Phase II&III] Overall Survival(OS)
Time Frame: Until 6 months after the last participant is enrolled, assessed minimum to 18 months.
|
Overall survival(OS) is defined as the time from the date of inclusion to the date of death, regardless of the cause of death.
|
Until 6 months after the last participant is enrolled, assessed minimum to 18 months.
|
[Phase II&III] Time to Treatment Failure(TTF)
Time Frame: through study completion, an expected average of 4.5 year.
|
TTF is defined as the time from the randomization date to the date of discontinuation of treatment, regardless of the cause.
|
through study completion, an expected average of 4.5 year.
|
[Phase II&III] Disease Control Rate(DCR)
Time Frame: through study completion, an expected average of 4.5 year.
|
DCR is defined as the percentage of subjects who were evaluated for complete response(CR), partial response(PR), and stable disease(SD) as the best response among from randomization to End of treatment(EOT).
|
through study completion, an expected average of 4.5 year.
|
[Phase II&III] Quality of life(QoL)
Time Frame: C1D1, C2D1, C4D1, C7D1, C10D1 (each cycle is 28 days) and study completion, up to 18 months.
|
To evaluate changes versus baseline using the EQ-5D.
|
C1D1, C2D1, C4D1, C7D1, C10D1 (each cycle is 28 days) and study completion, up to 18 months.
|
Incidence of Treatment-Emergent Adverse Events [Safety]
Time Frame: Up to 28 days after last investigational product administraion.
|
Number and Description of Adverse Events
|
Up to 28 days after last investigational product administraion.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sung-bae Kim, M.D., Ph.D, Asan Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 18, 2017
Primary Completion (Estimated)
January 30, 2024
Study Completion (Estimated)
March 31, 2024
Study Registration Dates
First Submitted
September 28, 2017
First Submitted That Met QC Criteria
October 16, 2017
First Posted (Actual)
October 20, 2017
Study Record Updates
Last Update Posted (Actual)
December 28, 2023
Last Update Submitted That Met QC Criteria
December 26, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Disease Attributes
- Breast Diseases
- Breast Neoplasms
- Recurrence
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Albumin-Bound Paclitaxel
Other Study ID Numbers
- 107CS-5
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent or Metastatic Breast Cancer
-
Daehwa Pharmaceutical Co., Ltd.CompletedRecurrent or Metastatic Breast CancerUnited States, Czechia
-
Sun Pharma Advanced Research Company LimitedCompletedRecurrent or Metastatic Breast CancerIndia
-
Cancer Institute and Hospital, Chinese Academy...QuestgenomicsUnknownRecurrent or Metastatic Breast CancerChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UnknownAdvanced Recurrent or Metastatic Breast CancerChina
-
Geron CorporationCompletedLocally Recurrent or Metastatic Breast CancerUnited States, Canada
-
Shanghai JMT-Bio Inc.Not yet recruitingFirst-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
-
AmgenCompletedCancer | Breast Cancer | Breast Neoplasms | Metastatic Cancer | Breast Tumors | Solid Tumors | Oncology | Tumors | Metastases | Locally Recurrent and Metastatic Breast CancerUnited States, Belgium, France
-
Nanogen Pharmaceutical Biotechnology Joint Stock...Vietstar Biomedical Research; MedProve IncCompletedBreast Cancer Recurrent | Breast Cancer Female | Breast Cancer MetastaticVietnam
-
Nanogen Pharmaceutical Biotechnology Joint Stock...Vietstar Biomedical Research; MedProve IncCompletedBreast Cancer Recurrent | Breast Cancer Female | Breast Cancer MetastaticVietnam
-
Korean Breast Cancer Study GroupUnknownMetastatic Breast Cancer | Recurrent Breast CancerKorea, Republic of
Clinical Trials on Oral paclitaxel
-
Athenex, Inc.PharmaEssentia; Zenith Technology Corporation LimitedCompletedSolid TumorNew Zealand, United Kingdom, Taiwan, Australia
-
Athenex, Inc.CompletedAngiosarcoma of SkinUnited States, United Kingdom, Taiwan, Hong Kong
-
Athenex, Inc.CompletedMetastatic Breast CancerArgentina, Chile, Colombia, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Panama, Peru
-
Daehwa Pharmaceutical Co., Ltd.CompletedRecurrent or Metastatic Breast CancerUnited States, Czechia
-
National Cancer Institute, NaplesActive, not recruiting
-
Institut fuer FrauengesundheitEisai GmbHRecruitingAssessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE)Breast Cancer Female | Breast Cancer Metastatic | Neoplasm, BreastGermany
-
Spanish Breast Cancer Research GroupCelgeneCompleted
-
Peking University Cancer Hospital & InstituteRecruitingGastric AdenocarcinomaChina
-
Athenex, Inc.Merck Sharp & Dohme LLCTerminated
-
Daehwa Pharmaceutical Co., Ltd.UnknownAdvanced Solid TumorHungary